Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs

Vittorio Montefusco, Francesca Gay, Stefano Spada, Lorenzo De Paoli, Francesco Di Raimondo, Rossella Ribolla, Caterina Musolino, Francesca Patriarca, Pellegrino Musto, Piero Galieni, Stelvio Ballanti, Chiara Nozzoli, Nicola Cascavilla, Dina Ben-Yehuda, Arnon Nagler, Roman Hajek, Massimo Offidani, Anna Marina Liberati, Pieter Sonneveld, Michele Cavo, Paolo Corradini, Mario Boccadoro, Vittorio Montefusco, Francesca Gay, Stefano Spada, Lorenzo De Paoli, Francesco Di Raimondo, Rossella Ribolla, Caterina Musolino, Francesca Patriarca, Pellegrino Musto, Piero Galieni, Stelvio Ballanti, Chiara Nozzoli, Nicola Cascavilla, Dina Ben-Yehuda, Arnon Nagler, Roman Hajek, Massimo Offidani, Anna Marina Liberati, Pieter Sonneveld, Michele Cavo, Paolo Corradini, Mario Boccadoro

Abstract

Extramedullary disease is relatively frequent in multiple myeloma, but our knowledge on the subject is limited and mainly relies on small case series or single center experiences. Little is known regarding the role of new drugs in this setting. We performed a meta-analysis of eight trials focused on the description of extramedullary disease characteristics, clinical outcome, and response to new drugs. A total of 2,332 newly diagnosed myeloma patients have been included; 267 (11.4%) had extramedullary disease, defined as paraosseous in 243 (10.4%), extramedullary plasmocytoma in 12 (0.5%), and not classified in 12 (0.5%) patients. Median progression-free survival was 25.3 months and 25.2 in extramedullary disease and non-extramedullary disease patients, respectively. In multivariate analysis the presence of extramedullary disease did not impact on progression-free survival (hazard ratio 1.15, P=0.06), while other known prognostic factors retained their significance. Patients treated with immunomodulatory drugs, mainly lenalidomide, or proteasome inhibitors had similar progression-free survival and progression-free survival-2 regardless of extramedullary disease presence. Median overall survival was 63.5 months and 79.9 months (P=0.01) in extramedullary and non-extramedullary disease patients, respectively, and in multivariate analysis the presence of extramedullary disease was associated with a reduced overall survival (hazard ratio 1.41, P<0.001), in line with other prognostic factors. With the limits of the use of low sensitivity imaging techniques, that lead to an underestimation of extramedullary disease, we conclude that in patients treated with new drugs the detrimental effect of extramedullary disease at diagnosis is limited, that lenalidomide is effective as are proteasome inhibitors, and that these patients tend to acquire a more aggressive disease in later stages. (EUDRACT2005-004714-32, NCT01063179 NCT00551928, NCT01091831, NCT01093196, NCT01190787, NCT01346787, NCT01857115).

Copyright© 2020 Ferrata Storti Foundation.

Figures

Figure 1.
Figure 1.
(A) Progression-free survival (PFS) and (B) overall survival (OS) according to extramedullary disease presence and type. EMD: extramedullary disease; EMP: extramedullary plasmocytoma; PO: paraosseous plasmocytoma.
Figure 2.
Figure 2.
Progression-free survival (PFS) according to extramedullary disease features. (A) PFS according to extramedullary disease (EMD) presence and size. (B) PFS according to single or multiple EMD localizations.
Figure 3.
Figure 3.
Progression-free survival (PFS2). EMD: extramedullary disease; EMP: extramedullary plasmocytoma; PO: paraosseous plasmocytoma.
Figure 4.
Figure 4.
Overall survival (OS) according to extramedullary disease (EMD) features. (A) OS according to EMD presence and size. (B) OS according to single or multiple EMD.

References

    1. Blade J, Fernandez de Larrea C, Rosinol L, Cibeira MT, Jimenez R, Powles R. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805–3812.
    1. Varettoni M, Corso A, Pica G, Mangiacavalli S, Pascutto C, Lazzarino M. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010; 21(2):325–330.
    1. Zamagni E, Patriarca F, Nanni C, et al. Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood. 2011;118(23):5989–5995.
    1. Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360–364.
    1. Minnema MC, van de Donk NW, Zweegman S, et al. Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome. Bone Marrow Transplant. 2008; 41(9):779–784.
    1. Perez-Simon JA, Sureda A, Fernandez-Aviles F, et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia. 2006;20(3):542–545.
    1. Pasmantier MW, Azar HA. Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases. Cancer. 1969;23(1):167–174.
    1. Thomas FB, Clausen KP, Greenberger NJ. Liver disease in multiple myeloma. Arch Intern Med. 1973;132(2):195–202.
    1. Roccaro AM, Mishima Y, Sacco A, et al. CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation. Cell Rep. 2015; 12(4):622–635.
    1. Besse L, Sedlarikova L, Greslikova H, et al. Cytogenetics in multiple myeloma patients progressing into extramedullary disease. Eur J Haematol. 2016;97(1):93–100.
    1. Bink K, Haralambieva E, Kremer M, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica. 2008;93(4):623–626.
    1. Hillengass J, Moulopoulos LA, Delorme S, et al. Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Blood Cancer J. 2017;7(8):e599.
    1. Cavo M, Terpos E, Nanni C, et al. Role of (18)F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017; 18(4):e206–e217.
    1. Wu P, Davies FE, Boyd K, et al. The impact of extramedullary disease at presentation on the outcome of myeloma. Leuk Lymphoma. 2009;50(2):230–235.
    1. Durie BG. The role of anatomic and functional staging in myeloma: description of Durie/Salmon plus staging system. Eur J Cancer. 2006;42(11):1539–1543.
    1. Landau H, Pandit-Taskar N, Hassoun H, et al. Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leuk Lymphoma. 2012;53(2):275–281.
    1. Masárová K, Stefanikova Z, Mistrik M, Batorova A. Effectiveness of lenalidomide and dexamethasone for the treatment of extramedullary plasmacytoma in patients with multiple myeloma: Report of two cases. Blood. 2014;124(21):5760.
    1. Rosinol L, Cibeira MT, Blade J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832–836.
    1. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
    1. Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016; 127(8):971–976.
    1. Gagelmann N, Eikema DJ, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. Haematologica. 2018;103(5):890–897.
    1. Zamagni E, Nanni C, Patriarca F, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92(1):50–55.
    1. Moreau P, Attal M, Caillot D, et al. Prospective evaluation of magnetic resonance imaging and [18F]fluorodeoxyglucose positron emission tomography-computed tomography at diagnosis and before maintenance therapy in symptomatic patients with multiple myeloma included in the IFM/DFCI 2009 Trial: results of the IMA-JEM Study. J Clin Oncol. 2017; 35(25):2911–2918.
    1. Reed V, Shah J, Medeiros LJ, et al. Solitary plasmacytomas: outcome and prognostic factors after definitive radiation therapy. Cancer. 2011;117(19):4468–4474.
    1. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125(20):3049–3058.
    1. Rasche L, Angtuaco EJ, Alpe TL, et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma. Blood. 2018;132(1):59–66
    1. Jiménez R, Rosinol L, Cibeira MT, et al. Incidence and outcome of soft-tissue plasmacytomas in patients with multiple myeloma before and after the introduction of novel drugs. Blood. 2017;130(Suppl 1):3140.
    1. Gay F, Magarotto V, Crippa C, et al. Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results. Blood. 2013;122(8):1376–1383.
    1. Palumbo A, Bringhen S, Larocca A, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. J Clin Oncol. 2014;32(7):634–640.
    1. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895–905.
    1. Gay F, Oliva S, Petrucci MT, et al. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017;31(8):1727–1734.
    1. Magarotto V, Bringhen S, Offidani M, et al. Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myeloma. Blood. 2016;127(9):1102–1108.
    1. Larocca A, Bringhen S, Petrucci MT, et al. A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. Leukemia. 2016;30(6):1320–1326.
    1. Bringhen S, Petrucci MT, Larocca A, et al. Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. Blood. 2014;124(1):63–69.
    1. Bringhen S, D’Agostino M, De Paoli L, et al. Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma. Leukemia. 2018;32(4):979–985.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera